UY31896A - DERIVATIVES OF 5- (4-METHANOSULPHONYL-PHENYL) -TIAZOL FOR THE TREATMENT OF ACUTE AND CHRONIC INFLAMMATORY DISEASES - Google Patents

DERIVATIVES OF 5- (4-METHANOSULPHONYL-PHENYL) -TIAZOL FOR THE TREATMENT OF ACUTE AND CHRONIC INFLAMMATORY DISEASES

Info

Publication number
UY31896A
UY31896A UY0001031896A UY31896A UY31896A UY 31896 A UY31896 A UY 31896A UY 0001031896 A UY0001031896 A UY 0001031896A UY 31896 A UY31896 A UY 31896A UY 31896 A UY31896 A UY 31896A
Authority
UY
Uruguay
Prior art keywords
acute
treatment
chronic inflammatory
methanosulphonyl
tiazol
Prior art date
Application number
UY0001031896A
Other languages
Spanish (es)
Inventor
Rubio Royo Victor
De La Hera Martinez Antonio
Alvarez De Mon Soto Melchor
Munoz Munoz Ana
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08380177A external-priority patent/EP2135864A1/en
Priority claimed from US12/139,661 external-priority patent/US7781594B2/en
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Publication of UY31896A publication Critical patent/UY31896A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

La invención se refiere al uso de un compuesto (I): o una sal, un profármaco y/o un solvato farmacéuticamente aceptable del mismo, en la preparación de un medicamento para el tratamiento de una enfermedad inflamatoria aguda o crónica, mediante la inhibición de la producción de al menos una citosina pro-inflamatoria seleccionada de TNF-alfa e IFN-gamma, o mediante la inmunomodulación de la quimiocina IL-8 y/o la citosina reguladora IL-10. La invención también se refiere a compuestos novedosos de fórmula (I´): o una sal, un profármaco y/o un solvato farmacéuticamente aceptable del mismo, una composición farmacéutica.The invention relates to the use of a compound (I): or a pharmaceutically acceptable salt, prodrug and / or solvate thereof, in the preparation of a medicament for the treatment of an acute or chronic inflammatory disease, by the inhibition of the production of at least one pro-inflammatory cytosine selected from TNF-alpha and IFN-gamma, or by immunomodulation of the chemokine IL-8 and / or the regulatory cytosine IL-10. The invention also relates to novel compounds of formula (I '): or a pharmaceutically acceptable salt, prodrug and / or solvate thereof, a pharmaceutical composition.

UY0001031896A 2008-06-16 2009-06-12 DERIVATIVES OF 5- (4-METHANOSULPHONYL-PHENYL) -TIAZOL FOR THE TREATMENT OF ACUTE AND CHRONIC INFLAMMATORY DISEASES UY31896A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08380177A EP2135864A1 (en) 2008-06-16 2008-06-16 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases
US12/139,661 US7781594B2 (en) 2008-06-16 2008-06-16 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases

Publications (1)

Publication Number Publication Date
UY31896A true UY31896A (en) 2010-01-29

Family

ID=43414178

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001031896A UY31896A (en) 2008-06-16 2009-06-12 DERIVATIVES OF 5- (4-METHANOSULPHONYL-PHENYL) -TIAZOL FOR THE TREATMENT OF ACUTE AND CHRONIC INFLAMMATORY DISEASES

Country Status (19)

Country Link
EP (1) EP2313382A1 (en)
JP (1) JP2011524352A (en)
KR (1) KR20110022679A (en)
CN (1) CN102083806A (en)
AR (1) AR072113A1 (en)
AU (1) AU2009259451B2 (en)
BR (1) BRPI0915325A2 (en)
CA (1) CA2728139A1 (en)
CO (1) CO6331429A2 (en)
IL (1) IL209801A0 (en)
MA (1) MA32473B1 (en)
MX (1) MX2010013978A (en)
NZ (1) NZ589894A (en)
RU (1) RU2495031C2 (en)
SA (1) SA109300384B1 (en)
TW (1) TWI403506B (en)
UY (1) UY31896A (en)
WO (1) WO2009153226A1 (en)
ZA (1) ZA201008877B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2961695B1 (en) * 2010-06-29 2012-07-06 Galderma Res & Dev USE OF COMPOUNDS IN THE TREATMENT OR PREVENTION OF SKIN DISORDERS
RU2502513C2 (en) * 2012-01-11 2013-12-27 Государственное бюджетное учреждение здравоохранения Свердловской области "Свердловский областной клинический психоневрологический госпиталь для ветеранов войн" (ГБУЗ СО "СОКП Госпиталь для ветеранов войн") Method of treating patients with multiple organ pathology using ozone therapy
MX2020005360A (en) * 2017-11-23 2020-08-13 Immunic Ag Dosage regimen of vidofludimus for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases.
KR102076936B1 (en) * 2019-08-12 2020-02-13 연세대학교 산학협력단 Composition including thiazole or salt thereof as active ingredients for preventing or treating allergic disease or atopic dermatitis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2877508B2 (en) * 1989-02-08 1999-03-31 アボツト・ラボラトリーズ 4-Hydroxythiazole as 5-lipoxygenase inhibitor
WO1996003392A1 (en) * 1994-07-27 1996-02-08 G.D. Searle & Co. Substituted thiazoles for the treatment of inflammation
ES2247604T3 (en) * 1995-06-12 2006-03-01 G.D. SEARLE & CO. COMPOSITIONS THAT INCLUDE A CYCLLOXYGENASA-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR.
AU7559200A (en) * 1999-10-12 2001-04-23 Japan Tobacco Inc. Hypertriglyceridemia remedies and antiobestics
CA2451981C (en) * 2001-08-13 2012-02-21 Janssen Pharmaceutica N.V. 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
US20050026902A1 (en) * 2003-01-31 2005-02-03 Timothy Maziasz Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents

Also Published As

Publication number Publication date
WO2009153226A1 (en) 2009-12-23
NZ589894A (en) 2011-08-26
SA109300384B1 (en) 2013-04-20
MX2010013978A (en) 2011-03-29
CA2728139A1 (en) 2009-12-23
TWI403506B (en) 2013-08-01
IL209801A0 (en) 2011-02-28
AR072113A1 (en) 2010-08-04
KR20110022679A (en) 2011-03-07
MA32473B1 (en) 2011-07-03
JP2011524352A (en) 2011-09-01
TW201010988A (en) 2010-03-16
RU2011101439A (en) 2012-07-27
AU2009259451A1 (en) 2009-12-23
CN102083806A (en) 2011-06-01
BRPI0915325A2 (en) 2015-10-27
CO6331429A2 (en) 2011-10-20
EP2313382A1 (en) 2011-04-27
ZA201008877B (en) 2012-02-29
RU2495031C2 (en) 2013-10-10
AU2009259451B2 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
UY30819A1 (en) DERIVATIVES OF PIRAZOL, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS
EA201491060A1 (en) NEW DERIVATIVES OF TRIFTOROMETHYLOROXIAZOLE AND THEIR APPLICATION FOR THE TREATMENT OF DISEASE
CO6382125A2 (en) QUINASE PROTEIN INHIBITORS
ECSP088902A (en) DERIVATIVES OF PIRAZOLO [3,4-D] -PIRIMIDINE USEFUL TO TREAT RESPIRATORY DISORDERS
MX2014000341A (en) Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease.
MX2010007375A (en) Novel lupane derivatives.
JP2013542247A5 (en)
DOP2006000170A (en) NEW DERIVATIVES OF ESPIROCROMANONA
AR062394A1 (en) USE OF COMPOUNDS AND DERIVATIVES OF 2,5-DIHYDROXIBENCEN FOR THE TREATMENT OF PSORIASIS
ECSP13012812A (en) IMMUNOSUPPRESSOR FORMULATIONS
UA109421C2 (en) PHARMACEUTICAL COMPOSITION CONTAINING SIGMA-RECEPTOR LIGANDS
GT201200164A (en) "NEW SPYROPIPERIDINE COMPOUNDS"
CR11208A (en) USEFUL PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS
ECSP12011703A (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS
EA200870302A1 (en) 1,3-DIOXANKARBONIC ACIDS
JP2009537554A5 (en)
WO2008098985A3 (en) Pharmaceutical composition for the treatment of il-8 mediated diseases
AR062390A1 (en) USE OF DERIVATIVES OF 2,5-DIHYDROXIBENGEN FOR THE TREATMENT OF HEMANGIOMS OR HEMANGIOBLASTOMAS
MX2021003739A (en) Quinolino-pyrrolidin-2-one derivative and application thereof.
UY30847A1 (en) USE OF DIANHYDROHEXITE MONONITRATE DERIVATIVES AS AGENTS FOR THE TREATMENT OF INTESTINAL DISORDERS
UY31896A (en) DERIVATIVES OF 5- (4-METHANOSULPHONYL-PHENYL) -TIAZOL FOR THE TREATMENT OF ACUTE AND CHRONIC INFLAMMATORY DISEASES
BR112013012665A2 (en) compound of formula (i), or a salt, prodrug or solvate thereof and pharmaceutical composition
JP2011012060A5 (en)
DOP2013000206A (en) INHIBITORS OF THE PEPTIDE DESFORMILASA
EP2593460A4 (en) 7, 9-nitrogen radical-4-oxo-4h-pyrido[l,2-a]pyrimidine-2-carboxylic acid benzylamide anti-virals

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181031